Used in cancer research, particularly in studies targeting hematologic malignancies and solid tumors. Acts as a potent inhibitor of bromodomain and extra-terminal (BET) proteins, which play a key role in the regulation of oncogene expression. Shows antitumor activity by suppressing the transcription of genes involved in cell proliferation and survival, such as MYC. Investigated for its potential in combination therapies with other anticancer agents to enhance efficacy and overcome resistance. Currently in preclinical and clinical development, primarily in oncology drug discovery programs.